BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

BIND Therapeutics, Inc.

BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer

June 29, 2010

Brings Clinical Leadership as BIND Prepares for Product Candidates to Enter the Clinic

CAMBRIDGE, Mass. – June 29, 2010 – BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today the appointment of Ed Schnipper, M.D., as Chief Medical Officer. Dr. Schnipper has more than 20 years of leadership experience in the successful clinical development of medicines for the pharmaceutical and biotechnology industries. Dr. Schnipper has been responsible for numerous clinical trial programs that resulted in successful development, approval and commercial growth for new therapeutic products in oncology and other therapeutic areas.

“We are thrilled to have Ed join our team. He has a distinguished track record in drug development, including being instrumental in directing the clinical trials that led to the FDA approval and successful commercial launch of the leading nanotechnology oncology drug, Doxil®,” said Scott Minick, President and Chief Executive Officer of BIND. “Ed is uniquely qualified to lead our clinical team and also collaborate with the recently-formed board of outstanding clinical advisors for BIND, as we bring our company’s first nanoparticle-based drug into the clinic in 2010.”

“This is a tremendous opportunity to create a new class of therapeutics through the Medicinal NanoengineeringTM of both existing and new drugs,” said Dr. Schnipper. “From my experience in developing drugs based on liposomes – considered the first generation of nanoparticle drugs – I view BIND’s targeted nanoparticle technology as a major advance in developing the next generation of best in class drugs using targeted therapeutics to increase efficacy and reduce toxicity. I am delighted to join the talented and experienced team at BIND in working to fulfill the enormous potential of this nanotechnology platform.”

Previously, Dr. Schnipper was Vice President of Clinical Development at ALZA Corporation, a specialty pharmaceutical company. In this role, Dr. Schnipper was responsible for the clinical development for new pharmaceutical products, as well as the Phase IV strategies for products in its pharmaceutical product portfolio and pipeline. Before joining ALZA, Dr. Schnipper served as Senior Vice President and Medical Director at SEQUUS Pharmaceuticals, where he was responsible for clinical and regulatory functions and a member of the Executive Committee and was instrumental in leading the successful FDA approval of the leading nanoparticle-based oncology drug, Doxil (liposomal doxorubicin). Prior to SEQUUS, Dr. Schnipper held various senior clinical positions at Hoffmann-La Roche.

About BIND Biosciences

BIND Biosciences, Inc., is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering platform to produce best in class drugs to provide significant improvement in the treatment of patients with serious diseases. BIND’s platform enables the design, engineering and manufacturing of therapeutic targeted nanoparticles with unprecedented control over drug pharmacokinetics, biodistribution, and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective, and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.

BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments and Endeavour Vision. For more information, please visit the company’s web site at www.bindbio.com.

Contacts

BIND Biosciences
Andrea Franz
Tel: 617-491-3400
afranz@bindbio.com

Media:
Kathryn Morris
The Yates Network
Tel: 845-635-9828
kathryn@theyatesnetwork.com